Anticoagulation Approach in Liver Cirrhosis

Indications for Anticoagulation

The American Association for the Study of Liver Diseases recommends anticoagulation in patients with recent (<6 months) portal vein thrombosis (PVT) with >50% occlusion of the main portal vein or involvement of the mesenteric veins, with selection of the anticoagulant based on the patient's Child-Pugh classification 1, 2, 3
Anticoagulation is indicated in symptomatic PVT with risk of intestinal ischemia, requiring urgent anticoagulation 4, 5
The European Association for the Study of the Liver suggests anticoagulation in patients with recent PVT (<6 months) and involvement of the mesenteric veins 2, 3
Anticoagulation is recommended in patients with PVT who are candidates for liver transplantation 5, 6

For Child-Pugh A and B patients, direct oral anticoagulants (DOACs), such as apixaban, are preferred due to their convenience and comparable or superior recanalization rates compared to vitamin K antagonists (VKAs) 1, 5, 6
In Child-Pugh C patients, low molecular weight heparin (LMWH) is the preferred option, while DOACs are not recommended due to increased risk of bleeding 5, 6

Screening for esophageal varices should be performed before initiating anticoagulation 5, 9
Adequate prophylaxis for variceal bleeding should be ensured in patients at risk 5, 9
Renal function should be assessed, particularly for LMWH and DOACs 1

Imaging studies (CT or MRI) should be performed every 3 months to assess treatment response 1, 2
Regular assessment of bleeding risk should be performed every 6 months 5, 6
Anticoagulation should be discontinued in case of active bleeding or significant increase in bleeding risk 5, 6

A minimum of 6 months of anticoagulation is recommended for symptomatic or progressive PVT 5, 6
Anticoagulation should be continued until liver transplantation in candidates 5, 6
In patients with complete or partial recanalization, anticoagulation should be continued with reevaluation by imaging every 3 months 1, 2

Anticoagulation does not significantly increase the risk of bleeding related to portal hypertension 3, 8
Recurrence of PVT after revascularization or treatment discontinuation occurs in up to 38% of patients 1, 3
The International Normalized Ratio (INR) should not be used to assess bleeding risk in patients with cirrhosis 7, 9